KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Research & Development: 2012-2024

Historic Research & Development for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to $210.4 million.

  • Xenon Pharmaceuticals' Research & Development rose 35.25% to $77.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $272.7 million, marking a year-over-year increase of 42.04%. This contributed to the annual value of $210.4 million for FY2024, which is 25.60% up from last year.
  • According to the latest figures from FY2024, Xenon Pharmaceuticals' Research & Development is $210.4 million, which was up 25.60% from $167.5 million recorded in FY2023.
  • Over the past 5 years, Xenon Pharmaceuticals' Research & Development peaked at $210.4 million during FY2024, and registered a low of $50.5 million during FY2020.
  • Its 3-year average for Research & Development is $161.2 million, with a median of $167.5 million in 2023.
  • Data for Xenon Pharmaceuticals' Research & Development shows a peak YoY spiked of 58.38% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Xenon Pharmaceuticals' Research & Development stood at $50.5 million in 2020, then soared by 49.36% to $75.5 million in 2021, then soared by 40.16% to $105.8 million in 2022, then soared by 58.38% to $167.5 million in 2023, then grew by 25.60% to $210.4 million in 2024.